Cytokinetics Inc (NASDAQ: CYTK) kicked off on Tuesday, down -1.04% from the previous trading day, before settling in for the closing price of $56.75. Over the past 52 weeks, CYTK has traded in a range of $25.98-$110.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 12.30%. While this was happening, its average annual earnings per share was recorded 6.02%. With a float of $113.74 million, this company’s outstanding shares have now reached $117.66 million.
The extent of productivity of a business whose workforce counts for 423 workers is very important to gauge. In terms of profitability, gross margin is -2886.73%, operating margin of -16148.37%, and the pretax margin is -17398.82%.
Cytokinetics Inc (CYTK) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cytokinetics Inc is 3.33%, while institutional ownership is 113.93%. The most recent insider transaction that took place on Sep 17 ’24, was worth 414,401. In this transaction EVP Research & Development of this company sold 7,300 shares at a rate of $56.77, taking the stock ownership to the 120,920 shares. Before that another transaction happened on Sep 16 ’24, when Company’s President & CEO sold 5,000 for $55.99, making the entire transaction worth $279,950. This insider now owns 397,456 shares in total.
Cytokinetics Inc (CYTK) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -1.35 earnings per share (EPS), lower than consensus estimate (set at -0.74) by -0.61. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.02% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to -22.79% drop over the previous five years of trading.
Cytokinetics Inc (NASDAQ: CYTK) Trading Performance Indicators
Take a look at Cytokinetics Inc’s (CYTK) current performance indicators. Last quarter, stock had a quick ratio of 10.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2111.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.37, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -4.86 in one year’s time.
Technical Analysis of Cytokinetics Inc (CYTK)
The latest stats from [Cytokinetics Inc, CYTK] show that its last 5-days average volume of 1.09 million was inferior to 2.27 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 75.33%. Additionally, its Average True Range was 2.26.
During the past 100 days, Cytokinetics Inc’s (CYTK) raw stochastic average was set at 44.66%, which indicates a significant decrease from 56.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.30% in the past 14 days, which was lower than the 50.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $56.21, while its 200-day Moving Average is $62.59. Now, the first resistance to watch is $57.99. This is followed by the second major resistance level at $59.82. The third major resistance level sits at $62.16. If the price goes on to break the first support level at $53.82, it is likely to go to the next support level at $51.48. The third support level lies at $49.65 if the price breaches the second support level.
Cytokinetics Inc (NASDAQ: CYTK) Key Stats
The company with the Market Capitalisation of 6.61 billion has total of 104,854K Shares Outstanding. Its annual sales at the moment are 7,530 K in contrast with the sum of -526,240 K annual income. Company’s last quarter sales were recorded 250 K and last quarter income was -143,320 K.
